Publications
Publications
- 2020
- HBS Working Paper Series
SSRIs and Non-SSRIs: Case Histories of Significant Medical Advances
By: Amar Bhidé, Srikant M. Datar and Katherine Stebbins
Abstract
Prozac is widely hailed as “a breakthrough drug for depression.” In 2020, the World Health Organization (WHO) estimated that over 264 million people worldwide suffer from depression, and 800,000 die by suicide each year. In 2014, researchers calculated the economic impact of depression—in terms of lost productivity, absenteeism, and treatment costs—to be USD$63 billion per year in the United States alone. Depression’s toll on lives and livelihoods prompted the WHO to place Prozac on its list of essential medicines in 2009.
Keywords
Health Care And Treatment; Technological Innovation; Innovation Strategy; Technology Adoption; Collaborative Innovation And Invention; Innovation And Invention; Governing Rules, Regulations, And Reforms
Citation
Bhidé, Amar, Srikant M. Datar, and Katherine Stebbins. "SSRIs and Non-SSRIs: Case Histories of Significant Medical Advances." Harvard Business School Working Paper, No. 20-135, July 2020.
About The Authors
